Company: MLSS
Filing Date: 2025-05-19
Form Type: 8-K
Source: 0001437749-25-017562
Chunk: 0

Company: MILESTONE SCIENTIFIC INC.
Filing Date: 2025-05-19
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02

-

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On May 14, 2025, the Board of Directors of Milestone Scientific Inc. (the “ Company”) unanimously by the directors in attendance appointed Shanth Thiyagalingam as an independent director of the Company. Mr. Thiyagalingam is currently the Chief Executive Officer of PainTEQ, a manufacturer of proprietary medical equipment. Prior to being named PainTEQ’s Chief Executive Officer, he served as Chief Operating Officer and Chief Commercial Officer. Prior to joining PainTEQ, he was General Manager APAC Neuromodulation of Abbott Laboratories, a multinational medical device and healthcare company, from 2018 to 2020, and Regional Director of Nevro Corporation, a medical device company and creator of HFX (an innovative, evidence-based treatment for chronic pain of the trunk and/or limbs). Prior thereto, he was Senior Marketing Manager of Stryker South Pacific (2012-2016), a manufacturer of proprietary medical devices, and Global Cardiac Surgery Marketing Manager (2011-2012) and ANZ Atrial Fibrillation Product Manager (2009-2011) of St. Jude Medical, a medical device company acquired by Abbott Laboratories, and a Virology Specialist Representative (2006-2009) at Bristol Meyers Squibb and a Medical Representative a(2003-2006) at Boehringer Ingelheim.

Mr. Thiyagalingam received a BS in Medical Science from Sydney University in 2002, a Masters in Marketing Management from Macquarie Graduate School of Management in 2010, and an MBA from Macquarie Graduate School of Management in 2014.

Item 7.01Regulation FD Disclosure